Rosuvastatin side effects
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin Side Effects: A Comprehensive Overview
Introduction to Rosuvastatin and Its Usage
Rosuvastatin is a potent statin widely prescribed for lowering cholesterol levels and reducing cardiovascular risk. While it is effective in managing hyperlipidemia, it is essential to understand the potential side effects associated with its use.
Myopathy and Muscle-Related Side Effects
Myotoxic Effects and Mitochondrial Alterations
Myopathy, characterized by muscle pain and weakness, is a common adverse effect of statins, including rosuvastatin. Experimental studies in rats have shown that rosuvastatin can induce mild myotoxic effects, such as increased creatine kinase (CK) levels, slight myoglobin elevation, and mild muscle necrosis. These effects were less severe compared to atorvastatin, another commonly used statin. Additionally, rosuvastatin caused minor mitochondrial dysfunction, indicated by a slight increase in lactate dehydrogenase (LDH) and a minor decrease in ATP and pAkt levels.
Comparison with Other Statins
In a meta-analysis comparing rosuvastatin with atorvastatin, rosuvastatin was found to be more efficacious in lowering LDL cholesterol without a significant increase in the risk of adverse events such as myalgia or elevated liver enzymes. This suggests that while rosuvastatin does have myotoxic potential, it may be better tolerated than some other statins.
Renal Safety
Risk of Renal Impairment
Concerns have been raised about the potential renal side effects of intensive LDL-C lowering with statins. A retrospective analysis of 40,600 participants in the rosuvastatin clinical development program found no significant increase in the risk of renal impairment or renal failure in patients treated with rosuvastatin compared to placebo. This indicates that rosuvastatin does not significantly affect renal function in patients without pre-existing advanced renal disease.
Hepatic Effects
Impact on Liver Mitochondria
High doses of rosuvastatin have been shown to cause morphological and functional alterations in the mitochondria of hepatocytes in hypercholesterolemic mice. These changes were dose-dependent, with higher doses leading to more severe mitochondrial damage and even premature death in some cases. However, doses close to the maximal therapeutic dose for humans did not significantly affect mitochondrial architecture or respiratory function after two months of treatment.
Cardiovascular and Vascular Effects
Cardioprotective Benefits
Rosuvastatin has been shown to have direct vascular and cardioprotective effects, including increased endothelial nitric oxide (NO) production and reduced myocardial necrosis following ischemia-reperfusion injury in mice. These benefits are attributed to the enhancement of endothelial function, which is a positive side effect of rosuvastatin therapy.
Effects in Hemodialysis Patients
In patients undergoing hemodialysis, rosuvastatin significantly lowered LDL cholesterol levels but did not reduce the incidence of cardiovascular events such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. This suggests that while rosuvastatin is effective in lowering cholesterol, its benefits in reducing cardiovascular events in this specific patient population may be limited.
Conclusion
Rosuvastatin is a highly effective statin for lowering cholesterol and reducing cardiovascular risk. However, it is associated with several side effects, including mild myotoxic effects, potential mitochondrial alterations in the liver, and a lack of significant impact on cardiovascular events in hemodialysis patients. Despite these side effects, rosuvastatin is generally well-tolerated and offers significant benefits in managing hyperlipidemia and improving vascular health. Patients should be monitored for any adverse effects, and the dosage should be adjusted accordingly to minimize risks.
Sources and full results
Most relevant research papers on this topic